nuhumun, a Medimorphic Biopharma Chrysalis brand, is pleased to announce the release of an ultra-luxury line of medicinal cannabinoid-based products.
GOLDEN, Colo., May 30, 2019 /PRNewswire/ -- nuhumun, a Medimorphic Biopharma Chrysalis brand, is pleased to announce the release of an ultra-luxury line of medicinal cannabinoid-based products. The new suite of products reflects the company’s dedication to setting new quality and efficacy standards in the industry while solving the most common problems consumers face with medicinal cannabis use such as accurate dosing, bioavailability, and convenience. The comprehensive line from nuhumun includes sublingual (under the tongue) sprays, soft gels and topical salves. In addition to popular flavor options and multiple dose strengths, the new products offer pharmaceutical industry precision and targeted formulations to ensure consumers, across lifestyles, have access to safe and effective options. “Our premium medicinal cannabis products always consider the needs of the consumer first,” said Patrick Denton, chief market officer at Medimorphic, nuhumun’s parent company. “With so many sub-par products on the market, we’re changing the paradigm by bringing nuhumun to consumers with proprietary technology that delivers maximum bioavailability, efficacy, and accuracy. Our consumers know exactly what they’re putting in their bodies.” nuhumun products use nanoemulsion suspension technology, advanced delivery systems, and precise micro-dosing to maximize efficacy.
nuhumun products will ship May 31, 2019. To place an order, please visit nuhumun.com. About nuhumun
About Medimorphic Biopharma Chrysalis Contact: Pamela M. Green
View original content to download multimedia:http://www.prnewswire.com/news-releases/nuhumun-releases-a-premium-line-of-medicinal-cannabis-based-products-300859313.html SOURCE nuhumun |